Spinal Trauma With Neurological Deficit
Conditions
Keywords
Spinal trauma, erythropoietin, dose escalation study
Brief summary
The social, psychological, economic burden of Spinal trauma with deficit is great, and there is no curative treatment. Erythropoetin (EPO) is promising, due to its neuroprotective effects demonstrated in vitro, in vivo in animal models and in a preliminary study including patients with stroke. The study primary end point is to find out the maximum tolerated dose of EPO. This is based on the occurrence of pulmonary embolism during a 14 day delay following EPO injection. Secondary end points include comparisons of EPO kinetics in blood and cerebrospinal fluid (CSF), study of EPO effects on several inflammatory and apoptotic bio markers and blood cell counts. The experimental design is a dose scale study (600 to 2400 UI/Kg), using a single dose of rHuEPO, (EPREX®). The EPO dose is defined using a Bayesian continuous reassessment Method (CRM). The sample size is expected for less than 20 patients. Eligible patients are patients aged 15 to 65 years, able to receive the EPO injection within 12 hours of a spinal trauma, without vital blood loss or associated diseases. The follow-up lasts 6 months.
Interventions
DRUGErythropoetin (rHuEPO, EPREX®)
Sponsors
Hospices Civils de Lyon
Study design
Allocation
RANDOMIZED
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
DOUBLE
Eligibility
Sex/Gender
ALL
Age
15 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Patient, male or female, aged 15 to 65 years, covered by a social insurance system, having given an informed consent (or attested by a third person if unable to sign, or parents consent in minors), within 12 hours of a spinal trauma, without vital organ deficiency from a non spinal origin
Exclusion criteria
* Impaired consciousness, * Treatment not given within 12 hours, * Cervical arthritis, * Respiratory failure requiring artificial ventilation, * Patient requiring blood transfusion superior to 2 units, * Uncontrolled severe hypertension, * Unstable hemodynamics, * Patient suffering from epilepsy, * Recent or uncontrolled angina pectoris, * Having received high doses of glucorticoïds, * Pregnant or breasting, * With more than 15 g/ml of haemoglobin, * With previous thrombo embolism disease, * With allergy to Low molecular Weight heparin, or * Participating in another interventional study
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Pulmonary embolism occurring during a 14 day delay following EPO injection. | — |
Secondary
| Measure | Time frame |
|---|---|
| Blood cells count biomarkers of inflammation and apoptosis: measured at Day 0 (Epo antibodies) D1, D3 and D 14 ICAM-1 Fas-Ligant M-30 IL-10 in blood and CSF. Clinical ASIA score, morbi-mortality Evolution of spinal MRI between D0 and D28. | — |
Outcome results
None listed